SNORA28: A Potential Cancer Drug Target and Biomarker (G677811)

Target Name: SNORA28

NCBI ID: G677811

SNORA28

Other Name(s): ACA28 | Small nucleolar RNA, H/ACA box 28 | small nucleolar RNA, H/ACA box 28

SNORA28: A Potential Cancer Drug Target and Biomarker

SNORA28 (ACA28) is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and kidneys. It is a member of the resource sharing family (SPOP) and is localized to the peri-apical region of the endoplasmic reticulum. SNORA28 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and the regulation of inflammation.

SNORA28 has also been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that SNORA28 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, these studies have shown that SNORA28 is involved in the regulation of cellular processes that are often associated with cancer progression, such as the regulation of apoptosis (programmed cell death) and the inhibition of cellular signaling pathways that promote cancer growth.

Due to its involvement in these processes, SNORA28 has been identified as a potential drug target (or biomarker) for cancer treatment. Studies have shown that inhibiting the activity of SNORA28 has the potential to inhibit the growth and progression of various types of cancer. For For example, researchers have shown that inhibiting the activity of SNORA28 using small molecules has the potential to inhibit the growth of breast cancer cells.

In addition to its potential as a cancer drug target, SNORA28 has also been shown to have potential as a biomarker for cancer diagnosis and treatment. For example, studies have shown that SNORA28 is expressed in various types of cancer and that its expression is often associated with the severity of these diseases. Additionally, these studies have shown that SNORA28 is involved in the regulation of cellular processes that are often associated with cancer diagnosis and treatment, such as the regulation of angiogenesis (the formation of new blood vessels) and the regulation of the immune response.

In conclusion, SNORA28 is a protein that is involved in a variety of cellular processes that are important for the regulation of health and disease. As a potential drug target (or biomarker) for cancer, SNORA28 has the potential to inhibit the growth and progression of various types of cancer. Additionally, SNORA28 may also be used as a biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of SNORA28 in these processes and to develop effective treatments for cancer.

Protein Name: Small Nucleolar RNA, H/ACA Box 28

The "SNORA28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets